NSE: APLLTD | BSE: 533573

Mid-range Performer

Download real time

1007.60 -5.60 (-0.55%)

38.94% Gain from 52W Low

46,428 NSE+BSE Volume

NSE 30 Jul, 2025 3:31 PM (IST)

19,805.7

Market Cap

High in industry

0.5

Beta 1Year

Very Low volatility

US FDA Approval

Alembic Pharma gets US FDA approval for Carbamazepine tablets, with a market size of $71 million See details

Alembic Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for APLLTD, BSE:533573 Alembic Pharmaceuticals Ltd.

Search Inside the pdf :

Alembic Pharmaceuticals Ltd.

07 May 2025

1007.60

-0.55%

Alembic Pharma (BUY): FY26 to be better than FY25

Buy: Alembic Pharmaceuticals Ltd.

BOB Capital Markets Ltd.

Revenue/EBITDA/ PAT grew 6.7%/8% and 19% above our estimates. EBITDA margin reported 20bps above estimates of 15.4% in 4QFY25

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Alembic Pharmaceuticals Ltd.

06 May 2025

1007.60

-0.55%

Exports outshine; API witnesses gradual recovery

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma (ALPM) delivered a better-than-expected performance in 4QFY25. A strong performance in export markets was offset partly by a muted show in domestic formulation (DF) segment.

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Alembic Pharmaceuticals Ltd.

12 Feb 2025

1007.60

-0.55%

Alembic Pharma (BUY): Earnings recovery on normalised Azithromycin base

Buy: Alembic Pharmaceuticals Ltd.

Target

BOB Capital Markets Ltd.

US and ROW sales grew above our estimates of 5% and 13% respectively, reporting growth of 10% each

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Alembic Pharmaceuticals Ltd.

04 Feb 2025

1007.60

-0.55%

In pursuit of a turnaround

Hold: Alembic Pharmaceuticals Ltd.

Recommendation Target

ICICI Securities Limited

Alembic Pharma’s (Alembic) Q3FY25 result was dragged by tepid performance in India and API biz. India biz growth has been weaker (5.8% in 9MFY25) for the last couple of quarters due to pressure in acute segment even though animal health biz has been growing <20%.

Alembic Pharmaceuticals Ltd. is trading above all available SMAs

Alembic Pharmaceuticals Ltd.

03 Feb 2025

1007.60

-0.55%

Muted India business and lower operating leverage drag earnings

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma (ALPM) delivered operationally in-line 3QFY25 performance. Higher interest outgo and tax led to lower-than-expected earnings for the quarter.

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Alembic Pharmaceuticals Ltd.

07 Nov 2024

1007.60

-0.55%

API/India trim earnings growth

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma’s (ALPM) 2QFY25 results came in below our estimates due to the deterioration in API business and higher operational costs.

Alembic Pharmaceutic.. has an average target of 962.33 from 3 brokers.

Alembic Pharmaceuticals Ltd.

07 Nov 2024

1007.60

-0.55%

Alembic Pharma (BUY): The worst is over; H2FY25 to be better than H1FY25

Buy: Alembic Pharmaceuticals Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Q2FY25 results were below our estimates on all fronts; however, ALPM expects H2 to be better than H1FY25 driven by healthy product mix

Alembic Pharmaceuticals Ltd. is trading above all available SMAs

Alembic Pharmaceuticals Ltd.

09 May 2024

1007.60

-0.55%

Alembic Pharma (HOLD): Strong margins; positives priced in

Hold: Alembic Pharmaceuticals Ltd.

BOB Capital Markets Ltd.

ALPM reported strong margin gains in Q4 on account of better utilisation of new facilities and traction in the US business

Alembic Pharmaceutic.. has an average target of 962.33 from 3 brokers.

Alembic Pharmaceuticals Ltd.

09 May 2024

1007.60

-0.55%

Exports drive earnings; weak show in DF segment

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma (ALPM) delivered better-than-expected 4QFY24 earnings,
led by better gross margin and improved off-take in the API segment. After
two consecutive years of weak financial performance, ALPM ended FY24
with 10%/14%/43% YoY growth in sales/EBIDTA/PAT to INR62b/INR9.3b/
INR6b.

Alembic Pharmaceuticals Ltd. is trading above all available SMAs

Alembic Pharmaceuticals Ltd.

06 Feb 2024

1007.60

-0.55%

First Light | Monthly Economic Buffet, State Bank Of India, JSW Steel, Ambuja Cements, Alembic Pharma, Century Plyboards, VST Tillers Tractors

Hold: Alembic Pharmaceuticals Ltd.

Target

BOB Capital Markets Ltd.

Monthly Economic Buffet: Economic Round-up January 2024. SBIN: Pension one-off hurts profitability. JSTL: Progressing on expansion but valuations fair. ACEM: Healthy quarter, sustainability key; retain HOLD. ALPM: Healthy quarter; PAT beat on low tax rate. CPBI: Margin stress across segments. VSTT: Poor demand dampens performance

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Is Alembic Pharmaceuticals Ltd. worth buying?

239 Votes:

Buy 84.1%

Sell 7.95%

Hold 7.95%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Neutral SEE REPORTS >

pdf